Some of the names on the move ahead of the open.» Read More
Check out which companies are making headlines after-the-bell Tuesday:
Tim Ramey, D.A. Davidson analyst, explains why he sees a buying opportunity in Herbalife.
Shares of Herbalife are dropping since David Einhorn questioned the company's disclosures during a conference call, with CNBC's Herb Greenberg.
CNBC's Herb Greenberg reports on shares of Herbalife falling 20% after influential investor David Einhorn asked the company serious questions during a conference call.
Chesapeake Energy announced it will terminate its FWPP and will separate CEO and chairman positions. Jon Najarian, OptionMonster.com and Fadel Gheit, Oppenheimer analyst, discuss the positive developments for the company.
The FMHR traders discuss the current state of the economy and the trade on Herbalife since David Einhorn questioned the company's disclosure. Stephen Weiss, Short Hills Capital; and CNBC's Bertha Coombs and Herb Greenberg weigh in.
CNBC's Bertha Coombs reports that Herbalife shares have halted.
CNBC's Seema Mody reports on which stocks are making big moves after hours, including Monster Beverage and Anadarko Petroleum.
Here are 10 of the top stock picks of three low-volatility, highly rated small-cap growth funds, ranked in inverse order of their number of “buy” ratings.
CNBC's Herb Greenberg knocked Herbalife last week for claiming it does a substantial amount of R&D, but not disclosing the amount it spends. Now, Herbalife offers a response.
Last week, I knocked Herbalife for claiming it does a bunch of R&D, but not disclosing the amount it spends on it. Then, later in the week, without fanfare, the nutritional supplement company updated the R&D section of its website to show the amount they spend on R&D and other stuff.
The Fast Money traders reveal their top three trades, with Josh Brown, of Fusion Analytics, who explains why JPMorgan is one of the best positioned banks in the nation, and Romit Shah, of Nomura, explains why Texas Instruments cut its forecast.
CNBC's Herb Greenberg raises the red flag on Heralife because he thinks they overhype their research. Timothy Ramey, D.A. Davidson, weighs in.
When a company brags about the amount of research it does, you would expect to “research and development” broken out as an expense somewhere in its SEC filings. At most companies, maybe, but not at Herbalife.
CNBC's Herb Greenberg takes a look at why Herbalife stock has managed to triple in price. Also, what happens when a CEO says one thing and files something completely different with the SEC.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Michael Johnson, Herbalife CEO, discusses his company's big earnings beat and 50% dividend boost, with Mad Money's Jim Cramer.
Jim Cramer’s researcher, Nicole Urken, takes a look at why there is limited near-term upside for Weight Watchers stock … with a nod toward linsanity
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Cramer makes the call on viewers' favorite stocks.